Tumor immunophenotype was characterized by a strong expression of conventional myeloid antigens (CD13, CD33, CD15, MPO), although no monocytic (CD14, CD64, CD11c, CD11b, lysozyme), megakaryoblastic (CD61, CD41) and lymphoid (CD7, CD19, iCD79a, CD56, CD2) markers were found. The gene discussed is ITGA2B; the disease is neoplasm.